---
id: 119
title: Epstein-Barr Virus (EBV) and Infectious Mononucleosis
category: organisms
subcategory: viruses
tags: [EBV, mononucleosis, mono, heterophile, PTLD, lymphoma]
difficulty: medium
---

## Question

How is EBV/infectious mononucleosis diagnosed and managed? Use the **"Monospot + Atypical Lymphocytes, Supportive Care, Avoid Ampicillin"** framework.

## Answer

### **Infectious Mononucleosis (IM) Presentation:**

**Classic Triad:**
- **Fever**
- **Pharyngitis** (exudative, often severe)
- **Lymphadenopathy** (posterior cervical most characteristic)

**Other Features:**
- **Splenomegaly** (50-60%) - risk of splenic rupture
- **Hepatomegaly**, mild ↑LFTs (transaminitis)
- **Fatigue** (can persist weeks to months)
- **Rash** (10%) - **maculopapular rash if given ampicillin/amoxicillin** (90% develop rash)

### **Diagnosis:**

| Test | Timing | Sensitivity | Notes |
|------|--------|-------------|-------|
| **Heterophile antibody (Monospot)** | **Week 1-2+** | **70-90%** (lower in young children <4 years) | **Quick, inexpensive**, false negatives early |
| **Atypical lymphocytes (>10%)** | **Week 1+** | Suggestive (not specific) | **Reactive T cells** (not infected B cells) |
| **EBV-specific serology** | Anytime | Gold standard | **VCA-IgM** (acute), **VCA-IgG** (past/current), **EBNA** (past infection, appears late) |

**EBV Serology Interpretation:**

| VCA-IgM | VCA-IgG | EBNA | Interpretation |
|---------|---------|------|----------------|
| **+** | **+** | **-** | **Acute infection** |
| **-** | **+** | **+** | **Past infection** (immune) |
| **-** | **-** | **-** | **Never infected** (susceptible) |

### **Management:**

**Supportive Care:**
- **Rest, hydration, NSAIDs/acetaminophen** for pain/fever
- **Avoid contact sports** for **4 weeks** (splenic rupture risk)
- **Avoid ampicillin/amoxicillin** (causes rash in 90%)

**Indications for Steroids (controversial):**
- **Airway obstruction** (severe tonsillar hypertrophy)
- **Severe hemolytic anemia** or **thrombocytopenia**
- **Not routinely recommended** for uncomplicated IM

**Antivirals:**
- **NOT effective** for acute IM (EBV latent in B cells)
- **Ganciclovir/valganciclovir** may be used for EBV reactivation in immunocompromised (PTLD)

## Key Points

### **Complications:**

**Hematologic:**
- **Hemolytic anemia** (cold agglutinins, IgM anti-i antibodies)
- **Thrombocytopenia**
- **Splenic rupture** (rare, 0.1-0.5%) - abrupt left upper quadrant pain, hypotension

**Neurologic:**
- **Encephalitis**, **aseptic meningitis**
- **Guillain-Barré syndrome**
- **Bell's palsy**

**Other:**
- **Airway obstruction** (tonsillar hypertrophy)
- **Hepatitis** (transaminitis common, jaundice rare)

### **EBV-Associated Malignancies:**
- **Burkitt lymphoma** (endemic in Africa, EBV+ in 95%)
- **Hodgkin lymphoma** (40-50% EBV+)
- **Nasopharyngeal carcinoma** (endemic in Southeast Asia)
- **Post-transplant lymphoproliferative disorder (PTLD)** (EBV-driven B-cell proliferation in transplant recipients)
- **Primary CNS lymphoma** (HIV+ patients)

### **PTLD (Post-Transplant Lymphoproliferative Disorder):**
- **EBV-driven** B-cell proliferation in transplant recipients
- **Risk factors:** EBV-seronegative recipient + EBV+ donor (primary infection), high immunosuppression
- **Treatment:** **Reduce immunosuppression**, **rituximab** (anti-CD20), **chemotherapy** (if aggressive)

### **Clinical Pearls:**
- **Monospot** (heterophile antibody) + atypical lymphocytes (>10%) = IM
- **Avoid ampicillin/amoxicillin** (90% develop rash)
- **Avoid contact sports × 4 weeks** (splenic rupture risk)
- **Supportive care** (rest, NSAIDs) - no antivirals for acute IM
- **VCA-IgM + VCA-IgG + EBNA-negative** = acute EBV
- **PTLD:** EBV-driven lymphoma in transplant recipients (reduce immunosuppression + rituximab)

## Sources

- [CDC: EBV Guidelines 2024]
- [IDSA: PTLD Management 2023]

## Media

N/A
